Drug Type Multi-specific antibody |
Synonyms TROY-Ig HER2 MsAb |
Target |
Mechanism 4-1BB modulators(Tumor necrosis factor receptor superfamily member 9 modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators), HER2 modulators(Receptor protein-tyrosine kinase erbB-2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Solid Tumors | Preclinical | CN | 17 Sep 2024 |